Safety study of Depigoid vaccine Dermatophagoides pteronyssinus or 50% Dermatophagoides
pteronyssinus / 50% Dermatophagoides farinae (500 DPP/ml), to treat allergic rhinitis or
rhinoconjunctivitis with or without asthma.
Primary variable: number of subjects [%] who experienced at least one immediate or delayed
systemic reaction of EAACI grade 2 or higher during the 4-month treatment period.